Shares of Molecular Templates (MTEM) have risen by over 30% since my September 2018 article pointed out that the "new" Takeda (TKPHF) agreement provided more validation for its Engineered Toxin Bodies ((ETB)) platform.
May's earnings update served as a reminder that I need to revisit this one, given that a couple of important programs are about to enter the clinic and data is expected from phase 2 studies evaluating MT-3724 (CD-20 targeting immunotoxin).
Chart
Figure 1: MTEM daily advanced chart (Source: Finviz)
When looking at charts, clarity often comes from taking a look